BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5

por Oien, Derek B., Sharma, Samanta, Hattersley, Maureen M., DuPont, Michelle, Criscione, Steven W., Prickett, Laura, Goeppert, Anne U., Drew, Lisa, Yao, Yi, Zhang, Jingwen, Chan, Ho Man
Publicado 2023

BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors

por Rhyasen, Garrett W., Yao, Yi, Zhang, Jingwen, Dulak, Austin, Castriotta, Lillian, Jacques, Kelly, Zhao, Wei, Gharahdaghi, Farzin, Hattersley, Maureen M., Lyne, Paul D., Clark, Edwin, Zinda, Michael, Fawell, Stephen E., Mills, Gordon B., Chen, Huawei
Publicado 2018

First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma

por Hamilton, Erika P., Wang, Judy S., Oza, Amit M., Patel, Manish R., Ulahannan, Susanna V., Bauer, Todd, Karlix, Janet L., Zeron-Medina, Jorge, Fabbri, Giulia, Marco-Casanova, Paola, Moorthy, Ganesh, Hattersley, Maureen M., Littlewood, Gillian M., Mitchell, Patrick, Saeh, Jamal, Pouliot, Gayle P., Moore, Kathleen N.
Publicado 2023

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells

por Criscione, Steven W., Martin, Matthew J., Oien, Derek B., Gorthi, Aparna, Miragaia, Ricardo J., Zhang, Jingwen, Chen, Huawei, Karl, Daniel L., Mendler, Kerrin, Markovets, Aleksandra, Gagrica, Sladjana, Delpuech, Oona, Dry, Jonathan R., Grondine, Michael, Hattersley, Maureen M., Urosevic, Jelena, Floc’h, Nicolas, Drew, Lisa, Yao, Yi, Smith, Paul D.
Publicado 2022

VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status

por Bizzaro, Francesca, Fuso Nerini, Ilaria, Taylor, Molly A., Anastasia, Alessia, Russo, Massimo, Damia, Giovanna, Guffanti, Federica, Guana, Francesca, Ostano, Paola, Minoli, Lucia, Hattersley, Maureen M., Arnold, Stephanie, Ramos-Montoya, Antonio, Williamson, Stuart C., Galbiati, Alessandro, Urosevic, Jelena, Leo, Elisabetta, Cavallaro, Ugo, Ghilardi, Carmen, Barry, Simon T., Bani, Maria Rosa, Giavazzi, Raffaella
Publicado 2021

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

por Lim, Emerson A., Bendell, Johanna C., Falchook, Gerald S., Bauer, Todd M., Drake, Charles G., Choe, Jennifer H., George, Daniel J., Karlix, Janet L., Ulahannan, Susanna, Sachsenmeier, Kris F., Russell, Deanna L., Moorthy, Ganesh, Sidders, Ben S., Pilling, Elizabeth A., Chen, Huifang, Hattersley, Maureen M., Das, Mayukh, Kumar, Rakesh, Pouliot, Gayle P., Patel, Manish R.
Publicado 2022